Moderna

MRNA

Market cap $15.5B

Moderna is undergoing a strategic shift, prioritizing infectious disease, oncology, and rare diseases to achieve cash break-even by 2028. 2026 is pivotal, with multiple oncology catalysts—especially Intismeran/Keytruda Phase II and III readouts—potentially driving future revenue and valuation. MRNA maintains a speculative 'Buy' rating for high-risk, long-term investors, supported by disciplined cost reductions and a maturing pipeline.

Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) said it expects 2025 revenue of approximately $1.9 billion, about $100 million above the midpoint of its previously communicated guidance of $1.6 to $2 billion. The company also raised its 2025 GAAP operating expense outlook by $200 million to a range of $5 to $5.2 billion and projects a year-end cash balance of approximately $8.1 billion, including a $0.6 billion drawdown from a recently announced $1.5 billion term loan facility.

Moderna also reiterates its expectations for revenue growth of up to 10% in 2026.

Moderna said on Monday it expects to report around $1.9  billion in sales for 2025, putting it near the upper end of its previously projected $1.6  billion to $2  billion forecast but well below revenue levels achieved during the COVID-19 pandemic.

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings Call Improves 2025 expected GAAP operating expenses by $200 million since 3Q25 Earnings Call Increases 2025 projected year-end cash balance to approximately $8.1 billion (unaudited) Reiterates plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026 Anticipates potential first approvals of flu and flu/COVID combination products in 2026 Expects pivotal trial data readouts in oncology, rare disease and infectious disease in 2026 CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 with a focus on growing sales, launching new infectious disease products and delivering pivotal readouts across oncology, rare disease and infectious disease portfolios.

In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ: MRNA) has quietly muscled its way into the top year-to-date performers, up more than 20% in just three trading days, and the technicals suggest the move may not be a fluke.

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.